GE HealthCare Secures CE Mark for New Cyclotron
The compact MINItrace Magni system aims to simplify on-site production of essential PET imaging isotopes in Europe.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Do you trust that new medical imaging tech will make diagnostic testing more accessible in your area?
GE HealthCare has received a CE Mark for its MINItrace Magni cyclotron, a compact system designed to produce fluorine-18, carbon-11, oxygen-15, and nitrogen-13. This approval allows for wider clinical distribution of the system across the European market.
Why it matters
Many PET imaging isotopes have very short half-lives, necessitating production near the point of patient care. This compact cyclotron enables hospitals to streamline isotope generation locally to improve access to diagnostic imaging.
The MINItrace Magni cyclotron occupies a 7.2 square meter footprint and utilizes a three-click automated workflow for beam tuning and target preparation. The system is designed to produce four primary PET isotopes.
The players
GE HealthCare
This global medical technology company specializes in diagnostic imaging and digital solutions for the healthcare industry.
The details
The system features a three-click workflow that automatically prepares the cyclotron and tunes the radiation beam. Additionally, the company expanded its PETtrace platform to support copper-64, an isotope being researched for potential use in prostate and breast cancer diagnostics and therapy.
Timeline
October 15, 2026: GE HealthCare announced the CE Mark approval for the MINItrace Magni.
Earlier in 2026: Zirconium-89 production debuted as part of the company platform.
The Big Picture
This development follows a pattern of expanding the PETtrace cyclotron solid target platform to facilitate more advanced oncological research. By integrating new isotopes, the company is bridging the gap between basic research and clinical applications in cancer care.
The system could allow more hospitals to produce short-lived isotopes on-site, potentially reducing wait times for crucial PET imaging scans. Patients may benefit from increased access to advanced diagnostics as regional medical centers adopt the technology.
The takeaway
The move reflects a growing trend toward decentralized medical isotope production to overcome the limitations of short radioactive half-lives. Healthcare providers should look to integrate these compact systems to enhance local diagnostic capabilities for complex patient cases.
Further reading
Learn more about the latest innovations in diagnostic oncology on the Cancer page.
Live Poll
Do you trust that new medical imaging tech will make diagnostic testing more accessible in your area?
